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Abstract. Therapeutic resistance in glioblastoma multiforme 
(GBM) has been linked to a subpopulation of cells with stem 
cell-like properties, the glioma stem cells (GSCs), responsible 
for cancer progression and recurrence. This study investigated 
the in vitro cytotoxicity of three chemotherapeutics, temo-
zolomide (TMZ), doxorubicin (Dox) and paclitaxel (PTX) 
on glioma cell lines, by analyzing the molecular mechanisms 
leading to DNA repair and cell resistance, or to cell death. 
The drugs were tested on 16 GBM cell lines, grown as neuro-
spheres (NS) or adherent cells (AC), by studying DNA damage 
occurrence by Comet assay, the expression by immunofluo-
rescence and western blotting of checkpoint/repair molecules 
and apoptosis. The three drugs were able to provoke a geno-
toxic injury and to inhibit dose- and time-dependently cell 
proliferation, more evidently in AC than in NS. The first cell 
response to DNA damage was the activation of the damage 
sensors (p-ATM, p-53BP1, γ-H2AX), followed by repair effec-
tors; the expression of checkpoint/repair molecules appeared 
higher in NS than in AC. The non-homologous repair pathway 
(NHEJ) seemed more involved than the homologous one (HR). 
Apoptosis occurred after long treatment times, but only a small 
percentage of cells in NS underwent death, even at high drug 
concentration, whereas most cells survived in a quiescent state 
and resumed proliferation after drug removal. In tumor speci-
mens, checkpoint/repair proteins were constitutively expressed 
in GBMs, but not in low-grade gliomas.
Introduction
High-grade malignant gliomas are among the most rapidly 
growing and lethal human tumors. Despite multimodal 
therapies, the prognosis of glioblastoma multiforme (GBM) 
remains poor and the tumor inevitably recurs. The failure of 
therapeutic treatments is mainly due to the diffusion modalities 
of the tumor and to several resistance mechanisms of cancer 
cells, such as elevated expression of drug efflux transporters 
(1-3), reduced sensitivity to apoptotic signals and increased 
expression of growth factors. A pivotal role in resistance is 
played by the ability of tumor cells to repair DNA damage 
caused by radiation and chemotherapeutic agents, through a 
DNA damage response (DDR) cascade (4-8).
Multiple complex pathways occur in the eukaryotic cells 
for the surveillance and repair of genetic material and cell 
cycle control. To DNA damage the cancer cells respond with: 
i) cell cycle arrest and lesion repair; ii) entry into apoptosis 
or other cell deaths; iii) proliferation without repairing the 
damage favouring the effects of more genetic mutations. In 
response to genotoxic stress, cells do not progress through 
the cycle until the stability of the DNA molecule is ensured: 
the MRN (Mre11-Rad50-Nbs1) sensor complex recruits the 
protein kinases ataxia telangiectasia mutated (ATM) and ataxia 
telangiectasia Rad3-related (ATR), that initiate a transduction 
cascade activating downstream effectors, including H2AX 
histone, 53 binding protein 1 (53BP1) and the checkpoint 
kinases Checkpoint 1 (Chk1) and Checkpoint 2 (Chk2). These 
last two molecules act as a molecular switch determining, 
through phosphorylation of tumor suppressor protein p53, cell 
cycle arrest in order to allow DNA damage repair (Fig. 1A). If 
the damage is too extensive, apoptosis is triggered (9). Double 
strand breaks (DSBs), the most dangerous DNA lesions 
in mammalian cells, are repaired by two main pathways: 
homologous recombination (HR) and non-homologous end 
joining (NHEJ) (10,11). The former takes place only in actively 
cycling cells, during the S/G2 phases and its key effector is 
RAD51 protein. The latter occurs during G0/G1 phases and is 
driven by DNA-dependent protein kinase (DNA-PK), which 
consists of a regulatory subunit (Ku70/Ku80 heterodimer) and 
a catalytic subunit (DNA-PKcs) (Fig. 1A).
Glioma stem cells (GSCs), responsible for GBM growth 
and recurrence, show a relative resistance to apoptosis and an 
increased DNA repair capacity (12-14). Thanks to preferential 
activation of DDR and to an increased Chk1/Chk2 activity, a 
delayed cell cycle may be a major resistance mechanism (7) 
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and Chk1/Chk2 inhibition is reported to sensitize to radio-
treatments (13).
Temozolomide (TMZ), doxorubicin (Dox) and paclitaxel 
(PTX) are drugs commonly used in the clinical practice of 
solid tumors. TMZ, an alkylating agent at present employed 
in the standard therapy of GBM, induces methylation in 
multiple sites on DNA. The O6-methylguanines (O6-meGs) 
are the most cytotoxic adducts and are normally repaired 
by the O6-methylguanine-DNA methyltransferase (MGMT). 
The hypermethylation of the MGMT promoter determines 
epigenetic silencing of the protein and correlates with a better 
prognosis (15). If the cell is MGMT-deficient, a futile mismatch 
repair (MMR) cycle is triggered with formation of DNA DSBs 
and activation of ATM/ATR-Chk1/Chk2 signaling, G2/M-cell 
cycle arrest and ultimately apoptosis (16-18) (Fig. 1B). The 
anthracycline Dox interferes with cell growth by intercalation 
between DNA paired bases, finally causing cell death. PTX 
acts as antimitotic drug determining apoptosis. Also Dox and 
PTX are reported to induce DNA strand breaks and a repair 
response in some cell types (19,20); their use on brain tumors 
is limited due to the poor blood-brain barrier (BBB) penetra-
tion capacity, even though their in vitro effectiveness on GBM 
cells and in glioma animal models is proven (21-23).
The present study explored the in vitro effects of TMZ, 
Dox and PTX on primary GBM cell lines, focusing the atten-
tion on TMZ and by investigating DNA damage extent and 
the molecular mechanisms leading to a repair response, i.e., a 
resistant phenotype, or to cell death.
Materials and methods
Cell lines, culture conditions and tumor specimens. Primary 
human GBM cultures were established from tumors surgi-
cally resected at the Department of Neurosurgery of CTO 
Hospital (Turin, Italy). Malignant glioma U87-MG and 
010627 cell lines were kindly supplied by Dr Rossella Galli 
(DIBIT San Raffaele, Milan, Italy). Ten cell lines were 
cultured, as previously described (24), in Dulbecco's modified 
Eagle's medium (DMEM)/F-12 supplemented with 20 ng/ml 
epidermal growth factor (EGF) and 10 ng/ml basic fibroblast 
growth factor (bFGF) for neurosphere (NS) assay and 6 cell 
lines in DMEM supplemented with 10% fetal bovine serum 
(FBS) for adherent cell (AC) growth (Table I). Both cultures 
were maintained at 37˚C in 5% O2 and 5% CO2. All cell lines 
were characterized for MGMT gene promoter and p53 gene 
status (24,25) (Table I). Experiments with primary GBM 
lines were carried out using cells from passages 10-20 and 
cultures were checked for Mycoplasma contamination before 
use (e-Myco™ Mycoplasma PCR Detection kit, iNtRON 
Biotechnology, Korea). Formalin-fixed paraffin-embedded 
(FFPE) brain tumor samples were collected from 8 GBMs, 
one pilocytic astrocytoma and one oligodendroglioma. The 
histological diagnosis was performed according to World 
Health Organization (WHO) guidelines (26). The study 
was in compliance with the local institutional review board 
and Committee on Human Research and with the ethical 
human-subject standards of the World Medical Association 
Declaration of Helsinki Research. Written informed consent 
was obtained from all patients.
Drug treatment and cytotoxicity assay. TMZ, Dox and PTX (all 
from Sigma-Aldrich Co., St. Louis, MO, USA) were dissolved 
in 100% dimethylsulfoxide (DMSO) for stock solutions. The 
final concentration of DMSO never exceeded 0.3% (v/v). All 
cell lines (10 NS and 6 AC) were treated with TMZ at increasing 
doses (5, 50, 100, 200 and 500 µM) and times [6, 24, 48, 72 
and 120 hours (h)]; eleven cell lines (7 NS and 4 AC) were 
treated with 1, 2 and 5 µM Dox at 2, 24, 48 and 72 h; ten cell 
lines (7 NS and 3 AC) were treated with 10, 100, 1,000 and 
5,000 nM PTX at 24, 48, 72 and 120 h. The drugs were added 
to dissociated NS cultures. After exposure, the cytotoxicity of 
the drugs was evaluated assessing the number of viable cells 
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide (MTT) assay (Roche, Diagnostic Corp., Indianapolis, 
IN, USA), measuring optical density at 570 nm (test wave-
length) and 660 nm (reference wavelength) by a microplate 
spectrophotometer (Synergy HT, BioTek Instruments Inc., 
Winooski, vT, USA). For NS, cell counts were also performed 
by trypan blue using a TC20 automated cell counter (Bio-Rad, 
Berkeley, CA, USA). Cytotoxicity was expressed as number of 
surviving cells as percentage of control (untreated cells). The 
concentration of the drugs which caused a 50% inhibition of 
Figure 1. Scheme of cell checkpoint/repair signaling after DNA damage (A) and mechanisms of cytotoxicity of TMZ (B) [modified from Bolderson et al (10) 
and Sarkaria et al (8)].
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the cell growth, defined IC50, was calculated for each cell line 
at 72 h by non-linear regression from the survival curves of 
Fig. 2A.
Comet assay. Cells were treated with different drug doses 
at various time-points and the occurrence of DNA damage 
induced by the drugs was investigated using the Comet (or 
single cell gel electrophoresis, SCGE) assay kit (Trevigen Inc., 
Gaithersburg, MD, USA) at neutral pH. Nuclei were labeled 
with SYBR Green I dye. Observations were made on a Zeiss 
Axioskop fluorescence microscope (Carl Zeiss, Oberkochen, 
Germany) equipped with an AxioCam5 MR5c and coupled 
to an Imaging system (Axiovision Release 4.5; Carl Zeiss). 
Cleaved DNA fragments caused by DSBs are detected as a 
tail (comet), the length of which is a measure of the DNA 
damage degree (27). Cells with comet tails were quantified as 
percentage over the total cell number and a visual score was 
assigned to the comets (28): score 0 representing undamaged 
cells (comets with no or barely detectable tails); score 1, 5-30% 
of migrated DNA; score 2, 31-70% of migrated DNA; score 3, 
>70% of migrated DNA (panel in Fig. 3G).
Determination of apoptosis. Apoptosis was evaluated on cells 
after treatment with TMZ and PTX and on tissue sections 
by in situ terminal deoxynucleotidyl transferase-mediated 
dUTP-biotin nick end-labeling (TUNEL) assay, using the 
in situ cell death detection kit, fluorescein (Roche) according 
to the manufacturer's protocols. Apoptotic indexes were 
calculated scoring 4 randomly selected fields and counting 
number of apoptotic cells over the total of viable cells which 
represented a quota in comparison with untreated cells.
Immunofluorescence (IF). IF was performed on NS and AC 
following TMZ and PTX treatments to monitor the activation 
of the damage/repair molecules p-ATM, p-Chk2, p-53BP1, 
γ-H2AX histone, HR effector RAD51, NHEJ effectors 
Ku70/Ku80 and DNA-PKcs. Cells were fixed for 20 min 
with 4% paraformaldehyde at room temperature, rinsed three 
times with PBS, blocked/permeabilized for 30 min with PBS 
containing 2% of the appropriate serum and 0.1% Triton X-100 
and finally stained with the following primary antibodies: 
monoclonal mouse anti-human γ-H2AX (Ser139) (05-636; 
Millipore, Bedford, MA, USA; dilution 1:200), monoclonal 
mouse anti-human p-ATM (Ser1981) (05-740; Millipore; 
dilution 1:100), polyclonal rabbit anti-human p-Chk2 (Thr68) 
(BK2197S; Cell Signaling Technology, Beverly, MA, USA; 
dilution 1:100), polyclonal rabbit anti-human p-53BP1 
(Ser25) (IHC-00053; Bethyl Laboratories, Inc., Montgomery, 
TX, USA; dilution 1:200), monoclonal mouse anti-human 
RAD51 (MS-988; NeoMarkers, Fremont, CA, USA; dilu-
tion 1:100), monoclonal mouse anti-human DNA-PKcs 
(MS-423; NeoMarkers; dilution 1:100) and monoclonal mouse 
anti-human Ku70/Ku80 (MS-286; NeoMarkers; dilution 1:200). 
Negative controls were obtained by omitting the primary anti-
body. Alexa Fluor® 488-AffiniPure goat anti-rabbit IgG and 
Alexa Fluor® 594-AffiniPure rabbit anti-mouse IgG (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA) 
were used as secondary antibodies. Cell nuclei were stained 
with 4',6-diamidino-2-phenylindole (DAPI) and examined 
under a Zeiss Axioskop fluorescence microscope.
Immunocytochemistry (ICC) and ιmmunohistochemistry 
(IHC). Due to the interfering spontaneous fluorescence of Dox, 
Table I. Cell lines with the IC50 values for each drug and the MGMT and p53 gene status.
Cell line IC50 (µM)a IC50 (µM)a IC50 (µM)a  Methylation status of Status of
 for TMZ for Dox for PTX MGMT promoter p53 gene
U87-MG NS  170 0.92 - Methylated Wild-type
010627 NS 135 - - Methylated Mutated
Cv10 NS  8.5 - - Methylated Wild-type
Cv21 NS    44 0.68 0.03 Methylated Wild-type
NO3 NS  120 0.85 0.044 Unmethylated Wild-type
NO4 NS 100 0.98 0.1 Methylated Mutated
NO6 NS  170 - 0.0094 Unmethylated Wild-type
CTO3 NS   97 1.85 0.066 Methylated Mutated
CTO5 NS 130 1.18 0.08 Unmethylated Wild-type
CTO15 NS 130 0.65 0.035 Unmethylated Mutated
U87-MG AC   42 0.72 - Methylated Wild-type
010627 AC 130 - - Methylated Mutated
Cv10 AC      5 - - Methylated Wild-type
NO3 AC    72 0.78 0.05 Unmethylated Wild-type
CTO3 AC   50 0.83 0.077 Methylated Mutated
CTO15 AC   46 0.67 0.027 Unmethylated Mutated
aIC50 was calculated at 72 h.
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ICC, instead of IF, was carried out on cells treated with Dox. 
IHC was performed on the 8 GBM and 2 low-grade tissues. 
The analyses were made using a ventana Full BenchMark® 
XT automated immunostainer (ventana Medical Systems 
Inc., Tucson, AZ, USA) and Ultraview™ Universal DAB 
Detection kit (ventana Medical Systems Inc.) as detection 
system. Heat-induced epitope retrieval (HIER) was performed 
in Tris-EDTA, pH 8.0. Primary antibodies were the same used 
for IF with the same dilutions. Negative controls were obtained 
by omitting the primary antibody.
Western blotting (WB). WB was performed as previously 
described (24) using the following primary antibodies: 
monoclonal mouse anti-human γ-H2AX (Ser139) (05-636; 
Millipore; dilution 1:1,000), monoclonal mouse anti-human 
p-ATM (Ser1981) (05-740; Millipore; dilution 1:2,000), poly-
Figure 2. Cytotoxic effect of TMZ, Dox and PTX on glioma cells. (A) Cell viability in neurospheres (NS) and adherent cells (AC) calculated at 72 h after the 
addition of various doses of TMZ (a and b), Dox (c and d) and PTX (e and f). Data are mean values ± SE of three independent experiments, each performed 
in triplicate. (B) Inhibitory effect of TMZ increasing doses (5, 50, 100 and 200 µM) at 72 h on NO3 NS (b-e) and on NO3 AC (g-j) growth; untreated NS and 
AC in (a) and (f), respectively; few surviving cells of NO3 NS line after 120-h treatment with 200 µM TMZ (k) and proliferation restarting after 30 days from 
treatment suspension (l). All x100 magnification.
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clonal rabbit anti-human p-Chk2 (Thr68) (BK2197S; Cell 
Signaling Technology; dilution 1:1,000), monoclonal mouse 
anti-human RAD51 (MS-988; NeoMarkers; dilution 1:500), 
and monoclonal mouse anti-human Ku70/Ku80 (MS-286; 
NeoMarkers; dilution 1:1,000). A polyclonal rabbit anti-human 
α-tubulin (LF-PA0146; LabFrontier, Seoul, Korea; dilution 
1:5,000) was used to normalize sample loading and transfer.
Statistical analysis. The level of significance was determined 
by a two-tailed Student's t-test. All quantitative data presented 
are the average value ± standard error (SE) from at least three 
independent determinations. Statistical significance was 
defined as p<0.05 or p<0.01.
Results
Cytotoxicity studies on GBM cell lines after TMZ, Dox and 
PTX treatments. NS lines were self-renewing, clonogenic, 
multipotent and expressing undifferentiation antigens; AC 
displayed a differentiation antigen profile (24). TMZ, Dox 
and PTX inhibited cell proliferation, both in NS and in AC by 
MTT assay, controlled by trypan blue method. The cytotoxic 
effect of the three drugs were dose- and time-dependent and 
more evident on AC than on NS (Fig. 2A-a-f). NS were resis-
tant to dosages of TMZ <10 µM, with the exception of CV10 
and Cv21 lines, that presented hypermethylation of MGMT 
promoter (Table I). Even high TMZ concentrations resulted 
in the survival of ≤30% of the cells in some NS lines. On the 
contrary, on most AC, TMZ concentrations <50 µM reduced 
cell growth to 50% after 72-h exposure. Compared with growth 
of untreated NS and AC (Fig. 2B-a and -f, respectively, from 
NO3 cell line, taken as a representative line), cell proliferation 
in NS (Fig. 2B-b-e) and AC adhesion (Fig. 2B-g-j) was hindered 
by TMZ in a dose and time-dependent manner. However, the 
growth inhibition in NS was not irreversible and the depletion 
of cells was not complete, even at high drug dosages. Even 
Figure 3. Comet assay on NO3 NS line. Comet assay on: untreated NO3 NS (A); NS after 50 µM TMZ for 24 h (B); after 50 µM TMZ for 72 h (C); after 200 µM 
TMZ for 72 h (D); after 2 µM Dox for 72 h (E); after 100 nM PTX for 72 h (F). Quantification of DNA damage in untreated cells (control) of NO3 NS and after 
72-h treatment with TMZ, Dox and PTX at various doses (G), by using an arbitrary visual score (upper panel); data are mean values ± SE of three independent 
experiments, each performed in triplicate.
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after 5-day treatment with high TMZ dosage (200 µM), a few 
single cells survived re-acquiring growth capacity within one 
month after treatment suspension (Fig. 2B-k and -l).
Dox uptake by NS and AC was evident in most cells 
already after 2 h with 2 µM drug and, after 24-h exposure, the 
number of viable cells showed 20% decrease with inhibition 
of clonogenicity in NS and of cell adhesion in AC. After 72-h 
treatment, 80% cells were dead. Also 100 nM PTX at 48 h 
inhibited evidently cell proliferation both in NS and in AC. 
After 5-day treatment a few single cells of NS lines survived 
re-acquiring growth capacity within one month after treatment 
suspension.
Evaluation of DNA damage by Comet assay. By Comet assay 
no damage was detectable on untreated NS (Fig. 3A) and AC 
(data not shown) and on NS treated with 50 µM TMZ for 24 h 
(Fig. 3B); a comet tail was evident only after 72-h exposure 
with 50 µM drug (Fig. 3C): >10% of cells showed a score-2-
length tail. Comets with score-3 length were visible in >50% 
of cells treated with 200 µM TMZ (Fig. 3D). The damage 
resulted more elevated in AC and in NS lines with methylated 
MGMT promoter. DNA lesions were revealed in NS (Fig. 3E) 
and even more in AC (data not shown) with 2 µM Dox at 72 h 
and the same effect but weaker was observed after 72-h treat-
ment with 100 nM PTX both in NS (Fig. 3F) and in AC (data 
not shown) with score-2 length tails. Quantification of cell 
damage by Comet assay in untreated and treated NO3 NS is 
reported in Fig. 3G.
Determination of cell apoptosis induced by drug treatment. 
Apoptosis was a late phenomenon, evident only after 72-h drug 
exposure, both in NS and AC (Fig. 4A and B). The frequency 
of apoptotic cells following treatment with increasing concen-
trations of TMZ for 6, 24 and 72 h is shown in Fig. 4C and D 
Figure 4. Evaluation of apoptosis in treated cells. Apoptosis after 100 µM TMZ for 72 h in NO3 NS (A) and in NO3 AC (B); TUNEL labeling, nuclei 
counterstained with DAPI, x400. Quantification of apoptotic cells after treatment with different doses and times of TMZ in NO3 NS (C) and AC (D) and after 
treatment with different doses and times of PTX in NO3 NS (E) and AC (F). Data are mean values ± SE of three independent experiments, each performed in 
triplicate. *,**Statistical significance (p<0.05 and p<0.01, two-tailed Student's t-test).
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Figure 5. Study of checkpoint/repair response in NO3 NS and AC. (A) Expression by immunofluorescence of checkpoint/repair proteins in untreated 
NO3 NS (a-g) and in cells treated with 100 µM TMZ for 48 h (h-n). (B) The same as above in untreated (a-g) and treated NO3 AC (h-n). (C) The same as 
above in NO3 AC treated with 100 nM PTX for 72 h (a-g): positivity of the antigens is evident at metaphasis level. Nuclei counterstained with DAPI. All x200 
magnification. (D) Expression by western blotting of p-ATM, p-Chk2, γ-H2AX and Ku70/Ku80 in 4 NS lines (Cv10, 010627, Cv21 and NO3), untreated and 
treated with 100 µM TMZ for 48 h. No band for RAD51 was detectable in any lines, not even after TMZ treatment. (E) Expression by immunocytochemistry 
of γ-H2AX, as indicator of DNA damage, in untreated NO3 NS (a, x400) and AC (e, x400) and after 50 µM TMZ for 48 h [(b) and (f) for NS and AC, respec-
tively, x400], after 5 µM Dox for 48 h [(c) and (g) for NS and AC, respectively, x400] and after combined treatment with 50 µM TMZ and 5 µM Dox for 48 h 
[(d) and (h) for NS and AC, x400 and x630, respectively]. (F) Levels of checkpoint/repair proteins at 24 (a) and 72 h (b) in NO3 NS, untreated (control) and 
treated with 100 µM TMZ, 2 µM Dox or 100 nM PTX.
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for NS and AC, respectively. In treated NS, apoptosis did not 
exceed 10-15% and it was ≤30% in AC. PTX-induced apop-
tosis was evidenced at 72 h already at concentration of 10 nM. 
At the highest drug dosages, the percentage of apoptotic cells 
was ≤20% in NS (Fig. 4E) and ≤30% in AC (Fig. 4F).
Studies of checkpoint/repair pathways in treated cells. The 
antigens of repair cascade resulted negative in untreated 
NS, with the exception of p-ATM, γ-H2AX, Ku70/Ku80, 
DNA-PKcs, moderately expressed in some lines (Fig. 5A-a-g). 
No expression was shown in untreated AC (Fig. 5B-a-g). The 
expression of all the sensors and effectors, except RAD51, was 
evident after 48-h exposure to 100 µM TMZ, both in NS and, 
at a minor extent, in AC (Fig. 5A and B-h-n). Expression of 
p-ATM, γ-H2AX, p-Chk2, Ku70/80 and RAD51 in 4 NS lines 
treated with TMZ was confirmed by WB analysis (Fig. 5D). 
Dox effects were the same as TMZ but earlier. γ-H2AX, 
indicator of DSBs, was evident after 48-h treatment with 
50 µM TMZ or 5 µM Dox, both in NS and in AC. Concurrent 
administration of the two drugs increased the effect with 
γ-H2AX expressed in ~90% of cells and a significant decrease 
in cell number (Fig. 5E-a-d for NS and -e-h for AC). All repair 
markers became negative after 72 h with high drug concentra-
tions (500 µM TMZ or 5 µM Dox): cells were dying or no 
longer able to activate the repair cascade. After 72-h treatment 
with 100 nM PTX, a moderate activation of checkpoint/repair 
response with a mild expression of all markers except RAD51 
was found in NS, whereas, interestingly, in treated AC, several 
cells appeared arrested in metaphase and with a strong expres-
sion of p-ATM, p-Chk2, p-53BP1, γ-H2AX, DNA-PKcs, 
Figure 6. (A) Immunohistochemical expression in GBM tissues of p-ATM, DAB, x200 (a); γ-H2AX, DAB, x200 (b); p-Chk2, DAB, x400 (c); RAD51, positive 
in scattered cells, DAB, x400 (d); DNA-PKcs, DAB, x200 (e); Ku70/Ku80, DAB, x200 (f). (B) Immunohistochemical expression of p-ATM in a pilocytic astro-
cytoma, DAB, x400 (a); γ-H2AX in an oligodendroglioma, DAB, x200 (b); p-Chk2 in an oligodendroglioma, DAB, x400 (c); RAD51 in an oligodendroglioma, 
DAB, x400 (d); DNA-PKcs in an oligodendroglioma, DAB, x200 (e); Ku70/Ku80 in an oligodendroglioma, DAB, x200 (f). (C) Evaluation of apoptosis in GBM 
tissue sections. Scattered apoptotic nuclei in palisades of circumscribed necroses (a) and in proliferating areas (b) of a GBM sample, TUNEL labeling, x400.
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Ku70/Ku80 (Fig. 5C-a-g). After 24 h from the beginning of 
treatments, the presence of activated damage sensors (p-ATM, 
p-53BP1, γ-H2AX, p-Chk2) was more evident, whereas at 
longer times (72 h), expression level of effectors (DNA-PKcs, 
Ku70/80) increased and that of sensor molecules decreased as 
repair proceeded (Fig. 5F).
Studies of checkpoint/repair and apoptosis in glioma tissues. 
p-ATM, γ-H2AX and the key proteins of NHEJ system, 
DNA-PKcs and Ku70/Ku80, were constitutively expressed in 
the GBM specimens studied, particularly in proliferation areas 
and in perinecrotic pseudopalisades (Fig. 6A-a, -b, -e and -f). 
p-ATM and γ-H2AX were sometimes positive in macrophages 
and reactive astrocytes. p-Chk2 and RAD51 expression 
was rather scarce and heterogeneous (Fig. 6A-c and -d) 
and p-53BP1 was not detectable. The two low-grade glioma 
tissues analyzed were almost negative for the markers, with 
the exception of p-ATM and γ-H2AX, poorly positive at level 
of mitoses (Fig. 6B). Apoptosis occurred in the palisades of 
circumscribed necroses and was scattered in the proliferating 
areas of GBM (29) (Fig. 6C).
Discussion
In this study we demonstrated that three commonly used anti-
cancer drugs, TMZ, Dox and PTX, were able, under in vitro 
conditions, to reduce significantly the number of viable cells 
in GBM NS lines and even more in AC lines, inhibiting clono-
genic growth in the former and hindering cell adhesion in the 
latter. The finding, as for TMZ, is in agreement with recent 
reports (30,31). Dox and PTX caused a more evident reduction 
of cell viability in comparison with TMZ, both in NS and in 
AC. IC50 values for TMZ and Dox at 72 h were, on average, 
higher for NS than for AC, proving that the former are more 
resistant than the latter, characterized by a more differentiated 
state. No significant differences in IC50 values for PTX was 
observed between NS and AC.
Cell lines with a hypermethylated MGMT promoter were 
mostly more sensitive to TMZ, but the data were in some cases 
discordant. MGMT expression indeed is not the only factor 
to be considered in evaluating TMZ response: p53 wild-type 
status is reported as fundamental to determine cell cycle 
arrest and the entry in the apoptotic process (32,33). In our 
data, among the cell lines with hypermethylated MGMT those 
with mutated p53 gene appeared more resistant to the action of 
TMZ than the ones with wild-type p53.
In NS cultures treated with TMZ or PTX, the depletion 
of cells was never complete even at high drug dosages; cells 
could resist the drugs in a non-proliferating state, as already 
observed for TMZ (30,31) and resumed proliferation within 
1-2 months after treatment suspension. The maintenance of a 
quiescent state and metabolic inertia may, therefore, represent a 
mechanism of genome protection in GSCs; the consequence is 
that antineoplastic treatments can have a cytostatic rather than 
a cytotoxic effect. Dox effect was more lethal and irreversible.
Apoptosis following treatments was a late phenomenon 
demonstrable only after 72 h, as already reported (18,34). In 
our observations, it was more evident in AC than in NS, but 
in both cases the frequency of apoptosis does not explain the 
level of reduction of viable cells, in agreement with the data of 
Beier et al (35).
By Comet assay we found that TMZ, Dox and, to lesser 
extent, PTX were able to produce in glioma cells a DNA 
damage, that increased proportionally with drug doses and 
times and was higher in AC than in NS lines, with the conse-
quent activation of the checkpoint/repair pathways. Moreover, 
we noted in some untreated NS lines a basal expression of some 
checkpoint/repair proteins, which was significantly elicited 
following drug exposure. After DNA injury also AC were able 
to trigger a repair response, although to a minor extent. Sensors 
of damage were the first proteins to be activated and they 
decreased with time, as the effectors increased and repair of 
lesions took place. From our data, NHEJ repair system activity 
seemed higher than the one of HR. It was reported that high 
tumor levels of DNA-PK correlate with poor survival in GBM 
patients treated with postsurgical radiation (36).
In GBM tissue specimens, we found a constitutive expres-
sion of checkpoint/repair proteins, not present in the low-grade 
tumors. At the beginning of tumorigenesis, DDR machinery 
acts as a protective mechanism against glioma progression, 
limiting the expansion of malignant clones with unstable 
genome (37). In glioma pathogenesis an aberrant constitutive 
activation of repair mechanisms was reported in response to 
DNA replication stress produced by oncogenes (38).
In conclusion, cell fate after treatments depends on the 
preferential activation of repair or apoptotic pathways. The 
intrinsic resistance to genotoxic therapies of malignant glioma 
cells could therefore be explained on one hand, by their ability 
to stop growth and survive in a quiescent state and, on the 
other hand, by the involvement of an enhanced DNA damage 
signaling. Moreover, we demonstrated that also Dox and PTX 
would be effective cytotoxic/cytostatic agents, similarly to 
TMZ, on glioma cells and, once the way to cross the BBB is 
found (39,40), they could be potentially useful in the GBM 
treatment. Targeted inhibition of the DNA repair factors could, 
therefore, be useful to sensitize malignant gliomas to geno-
toxic treatments and to improve therapeutic strategies.
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